Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
A series of in vitro studies designed to ascertain the potential in vivo thrombogenicity of human factor IX-containing concentrates is described. Using concentrates obtained from several different Centres the fibrinogen clotting time with some preparations was less than 6 h and/or the recalcification time of normal plasma was shortened. In some preparations, however, the plasma recalcification time was lengthened.Further studies revealed that all diluted factor-IX concentrates generated thrombin after recalcification, and that the rate of thrombin generation appeared to be characteristic of a particular preparation. This characteristic has been designated the TGt,,, which is the incubation period in minutes, after recalcification, required to obtain a 50 s clotting time of a fibrinogen substrate. The TGt,, was found to correlate most strongly with recalcification time of celite exhausted plasma (P c O.OOI), but no correlation was observed between it and the immunological antithrombin III or factor-VIII antigen levels. Evidence is presented which suggests that the thrombin generation test and recalcification time of celite exhausted plasma may represent suitable in uitro quality control assays for factor-IX concentrates.Preparations of human coagulation factor concentrates containing factor IX have been available for many years and were originally prepared to meet the therapeutic needs of patients with Christmas Disease (Soulier et al, 1964). Many of these preparations also contain factors 11, VII and X and with their increasing availability has come a tendency to use them in haeniorrhagic states associated with liver disease, oral anticoagulant overdosage and in the neonate (Soulier et a!, 1969).Within the last z years several reports have appeared which suggest that certain factor IXcontaining concentrates have been associated with such phenomena as thrombophlebitis, localized arterial and venous thrombosis, pulmonary cmboli, and even disseminated intravascular coagulation (Kasper
A series of in vitro studies designed to ascertain the potential in vivo thrombogenicity of human factor IX-containing concentrates is described. Using concentrates obtained from several different Centres the fibrinogen clotting time with some preparations was less than 6 h and/or the recalcification time of normal plasma was shortened. In some preparations, however, the plasma recalcification time was lengthened.Further studies revealed that all diluted factor-IX concentrates generated thrombin after recalcification, and that the rate of thrombin generation appeared to be characteristic of a particular preparation. This characteristic has been designated the TGt,,, which is the incubation period in minutes, after recalcification, required to obtain a 50 s clotting time of a fibrinogen substrate. The TGt,, was found to correlate most strongly with recalcification time of celite exhausted plasma (P c O.OOI), but no correlation was observed between it and the immunological antithrombin III or factor-VIII antigen levels. Evidence is presented which suggests that the thrombin generation test and recalcification time of celite exhausted plasma may represent suitable in uitro quality control assays for factor-IX concentrates.Preparations of human coagulation factor concentrates containing factor IX have been available for many years and were originally prepared to meet the therapeutic needs of patients with Christmas Disease (Soulier et al, 1964). Many of these preparations also contain factors 11, VII and X and with their increasing availability has come a tendency to use them in haeniorrhagic states associated with liver disease, oral anticoagulant overdosage and in the neonate (Soulier et a!, 1969).Within the last z years several reports have appeared which suggest that certain factor IXcontaining concentrates have been associated with such phenomena as thrombophlebitis, localized arterial and venous thrombosis, pulmonary cmboli, and even disseminated intravascular coagulation (Kasper
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.